

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

CCRF-CEM

RRID:CVCL_0207

Type: Cell Line

Proper Citation

RRID:CVCL_0207

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0207

Proper Citation: RRID:CVCL_0207

Description: Cell line CCRF-CEM is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Childhood T acute lymphoblastic leukemia

Defining Citation: [PMID:1086134](#), [PMID:2041050](#), [PMID:2140233](#), [PMID:2144611](#), [PMID:2255914](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3335022](#), [PMID:3495441](#), [PMID:3874327](#), [PMID:4363409](#), [PMID:5224274](#), [PMID:6198871](#), [PMID:6582512](#), [PMID:6600440](#), [PMID:6954533](#), [PMID:7630190](#), [PMID:7888679](#), [PMID:8127147](#), [PMID:8547074](#), [PMID:8641406](#), [PMID:9108419](#), [PMID:9290701](#), [PMID:9331090](#), [PMID:9510473](#), [PMID:9557624](#), [PMID:9685479](#), [PMID:9738977](#), [PMID:9787181](#), [PMID:9823951](#), [PMID:9933131](#), [PMID:10071127](#), [PMID:10700174](#), [PMID:10739008](#), [PMID:10769646](#), [PMID:11226526](#), [PMID:11565033](#), [PMID:14278051](#), [PMID:14500364](#), [PMID:15472075](#), [PMID:15748285](#), [PMID:16408098](#), [PMID:17088437](#), [PMID:17117183](#), [PMID:17170727](#), [PMID:17308084](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20922763](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22628656](#), [PMID:22675565](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25070259](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:29718670](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31394625](#), [PMID:31733513](#), [PMID:35354797](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-7 clinical proteomics reference material cell line panel., Part of: NCI-60 cancer cell line panel., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia -

CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CCRF-CEM

Synonyms: CCRF/CEM, CCRFCEM, CCRF.CEM, CCRF CEM, CCRF, CEM, CEM-CCRF, CEM-CCRF (CAMR), CCRF/CEM/0, CEM/0, CEM-0, CCRF-CEM/S, GM03671, GM03671C

Cross References: BTO:BTO_0000736, CLO:CLO_0002334, CLO:CLO_0015478, CLO:CLO_0050143, EFO:EFO_0002128, MCCL:MCC:0000096, MCCL:MCC:0000097, CLDB:cl675, CLDB:cl676, CLDB:cl677, AddexBio:C0003001/32, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CCL-119, ATCC:CRL-7916, ATCC:CRL-8436, ATCC:CRM-CCL-119, BCRC:60137, BCRJ:0063, BioGRID_ORCS_Cell_line:1318, BioSample:SAMN00808493, BioSample:SAMN01821675, BioSample:SAMN03471121, BioSample:SAMN03471203, BioSample:SAMN03472050, BioSample:SAMN03472700, BioSample:SAMN03472808, BioSample:SAMN03473385, cancercellines:CVCL_0207, CCRID:3101HUMTCHu147, CCRID:4201HUM-CCTCC00219, CCTCC:GDC0219, Cell_Model_Passport:SIDM00121, ChEMBL-Cells:ChEMBL3307641, ChEMBL-Targets:ChEMBL382, ChEMBL-Targets:ChEMBL393, CLS:300147, Coriell:GM03671, Cosmic:683716, Cosmic:721708, Cosmic:801728, Cosmic:846384, Cosmic:850198, Cosmic:875863, Cosmic:897449, Cosmic:905952, Cosmic:913411, Cosmic:919157, Cosmic:922674, Cosmic:932765, Cosmic:933544, Cosmic:974251, Cosmic:1012060, Cosmic:1037690, Cosmic:1044252, Cosmic:1070703, Cosmic:1071876, Cosmic:1092595, Cosmic:1115588, Cosmic:1118462, Cosmic:1127261, Cosmic:1151774, Cosmic:1175854, Cosmic:1176599, Cosmic:1191691, Cosmic:1224367, Cosmic:1226857, Cosmic:1247870, Cosmic:1281365, Cosmic:1305336, Cosmic:1330503, Cosmic:1375587, Cosmic:1483363, Cosmic:1509201, Cosmic:1523831, Cosmic:1524793, Cosmic:1639635, Cosmic:1664520, Cosmic:1760519, Cosmic:1998437, Cosmic:2165706, Cosmic:2301560, Cosmic:2361364, Cosmic:2433754, Cosmic:2458763, Cosmic:2462863, Cosmic:2602911, Cosmic:2649235, Cosmic:2649237, Cosmic:2668294, Cosmic-CLP:905952, DepMap:ACH-001738, DSMZ:ACC-240, DSMZCellDive:ACC-240, ECACC:85112105, EGA:EGAS00001000978, GDSC:905952, GEO:GSM2116, GEO:GSM50193, GEO:GSM50257, GEO:GSM236780, GEO:GSM236816, GEO:GSM743457, GEO:GSM750806, GEO:GSM799345, GEO:GSM799408, GEO:GSM1153416, GEO:GSM1178011, GEO:GSM1178012, GEO:GSM1178013, GEO:GSM1181330, GEO:GSM1181347, GEO:GSM1374445, GEO:GSM1669670, GEO:GSM2124653, GEO:GSM5137708, IARC_TP53:13197, IARC_TP53:21218, IGRhCellID:CCRFCEM, IPD-IMGT/HLA:10403, IZSLER:BS TCL 11, JCRB:IFO50412, JCRB:JCRB0033, JCRB:JCRB9023, KCLB:10119, LINCX_LDP:LCL-1012, Lonza:647, NCBI_Iran:C105, NCI-DTP:CCRF-CEM, PharmacDB:CCRFCEM_190_2019, PRIDE:PXD003539, PRIDE:PXD005940, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD023662, PRIDE:PXD030304, Progenetix:CVCL_0207, PubChem_Cell_line:CVCL_0207, RCB:RCB1980, SKY/M-FISH/CGH:2784, TKG:TKG 0563, Wikidata:Q54809015

ID: CVCL_0207

Record Creation Time: 20220427T215446+0000

Record Last Update: 20260913T002322+0000

Ratings and Alerts

No rating or validation information has been found for CCRF-CEM.

Warning: Discontinued: ATCC; CRL-7916

Population: Caucasian., Part of: NCI-7 clinical proteomics reference material cell line panel., Part of: NCI-60 cancer cell line panel., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zhang H, et al. (2026) A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRP?-Independent Mechanism. *Molecular cancer therapeutics*, 25(1), 21.

He L, et al. (2026) SATB1 regulates TXNIP inhibiting invasion and infiltration in T-cell acute lymphoblastic leukemia. *Cancer gene therapy*, 33(1), 55.

Zhou Y, et al. (2026) Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. *Cells*, 15(1).

Enlund S, et al. (2026) Uncovering a role for METTL13 in malignant transformation of human hematopoietic stem cells and in the progression of pediatric leukemia. *Cell death & disease*, 17(1).

Hu H, et al. (2026) ?Pharma: A microfluidic, AI-driven pharmacotyping platform for single-cell drug sensitivity prediction in leukemia. *Med (New York, N.Y.)*, 7(3), 100966.

Ngangoue MO, et al. (2026) Natural Products in Gambeya lacourtiana (Sapotaceae): Identification, In Vitro Cytotoxicity, and Deep Learning-Based Pharmacokinetic Prediction. *Chemistry & biodiversity*, 23(5), e02045.

Yagüe-Capilla M, et al. (2026) IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion. *Molecular oncology*.

Ibrahim NK, et al. (2025) SOD2 is a regulator of proteasomal degradation promoting an adaptive cellular starvation response. *Cell reports*, 44(4), 115434.

Yang C, et al. (2025) A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity. *Cell reports. Medicine*, 6(10), 102409.

Vrana C, et al. (2025) Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia. *PloS one*, 20(6), e0324443.

Matar S, et al. (2025) Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile. *Molecular cancer therapeutics*, 24(6), 816.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. *EBioMedicine*, 110, 105459.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Calbert ML, et al. (2024) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. *Molecular cancer therapeutics*, 23(5), 683.

González-Novo R, et al. (2023) 3D environment controls H3K4 methylation and the mechanical response of the nucleus in acute lymphoblastic leukemia cells. *European journal of cell biology*, 102(3), 151343.

de Lope-Planelles A, et al. (2023) Mechanical stress confers nuclear and functional changes in derived leukemia cells from persistent confined migration. *Cellular and molecular life sciences : CMLS*, 80(11), 316.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. *Cancer cell*, 41(12), 2136.

Lameris R, et al. (2023) A bispecific T cell engager recruits both type 1 NKT and V α 9V β 2-T cells for the treatment of CD1d-expressing hematological malignancies. *Cell reports. Medicine*, 4(3), 100961.

Xu Y, et al. (2022) The KRAS-G12D mutation induces metabolic vulnerability in B-cell acute lymphoblastic leukemia. *iScience*, 25(3), 103881.

Yamato M, et al. (2022) DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. *Molecular cancer therapeutics*, 21(4), 635.